Shun Lu et al. enrolled 444 patients and found that immunotherapies plus bevacizumab and chemotherapy was associated with a statistically significant and clinically meaningful improvement in patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy [32]. This evidence concerns the gene EGFR and non-small cell squamous lung carcinoma.